8-K: Qualigen Therapeutics Overhauls Leadership, Board, Auditor

Qualigen Therapeutics announced significant changes to its executive team, Board of Directors, and independent auditor, following a recent private placement offering.

Summary

• WithumSmith+Brown, PC resigned as the independent registered public accounting firm, effective October 1, 2025.
• Macias Gini & OConnell LLP (MGO) was appointed as the new independent registered public accounting firm, effective October 3, 2025.
• Jiawei Wang was appointed Co-Chief Executive Officer, effective October 2, 2025.
• Koti Meka was appointed Chief Financial Officer, effective October 2, 2025.
• Kevin Chen, Chad Chen, and Jie Sheng were appointed to the Board of Directors.
• Jie Sheng was appointed Chairman of the Audit Committee, with Graydon Bensler and Chad Chen as members.
• Chad Chen, Kevin Chen, and Jie Sheng were appointed as members of both the Nominating and Corporate Governance Committee and the Compensation Committee.
• Cody Price, Robert Lim, and Campbell Becher resigned from the Board of Directors; Mr. Becher remains President.
• The company previously received an explanatory paragraph in its 2024 audit report regarding substantial doubt about its ability to continue as a going concern.
• Material weaknesses in internal control over financial reporting were identified, including insufficient accounting personnel, lack of effective IT General Controls, and inadequate documentation of processes.

Sentiment

Score: 4

Explanation: While the company is bringing in experienced leadership and board members, and pursuing new strategic initiatives, the underlying issues of a 'going concern' explanatory paragraph and material weaknesses in internal controls are significant negatives that overshadow the positive changes. The auditor change, though amicable, occurs in this context. The capital raise is positive, but the financial health concerns remain prominent.

Positives

• Appointment of experienced executives, Jiawei Wang and Koti Meka, both with significant experience from Faraday Future, including capital raising and financial management.
• Expansion of the Board of Directors with new members bringing diverse expertise in law, finance, and operations.
• Strengthening of corporate governance through new committee appointments, including a new Audit Committee Chairman.
• The company is actively pursuing crypto and web3 strategic initiatives to accelerate global growth.

Negatives

• The previous auditor, WithumSmith+Brown, PC, included an explanatory paragraph in the 2024 audit report regarding substantial doubt about the company's ability to continue as a going concern.
• Material weaknesses in internal control over financial reporting were identified, including insufficient accounting personnel for segregation of duties, lack of effective IT General Controls, and inadequate documentation of processes.
• The resignation of the previous auditor, although stated as not due to disagreements, occurred amidst these internal control weaknesses and going concern issues.

Risks

• Substantial doubt about the company's ability to continue as a going concern, as noted in the previous auditor's report for the fiscal year ended December 31, 2024.
• Material weaknesses in internal control over financial reporting, specifically: (i) lack of sufficient personnel within the accounting function to adequately segregate duties, (ii) lack of designed and implemented effective Information Technology General Controls (ITGC) related to access controls to financial accounting systems, and (iii) lack of formalized documentation of its processes and controls that could be evaluated for proper design and implementation.

Future Outlook

The company aims to execute its long-term growth strategy and build lasting shareholder value through strengthened leadership, new board expertise, and a renewed commitment to transparency and compliance. It is also actively pursuing crypto and web3 strategic initiatives to accelerate global growth.

Management Comments

• "With strengthened leadership, new board expertise, and a renewed commitment to transparency and compliance, we are well positioned to execute our long-term growth strategy and build lasting shareholder value." Kevin Richardson, Co-CEO.

Industry Context

The appointments of executives and directors with strong ties to Faraday Future Intelligent Electric Inc. and experience in capital markets, including a successful IPO, suggest a strategic pivot or significant influence from new investors. The company's stated pursuit of 'crypto and web3 strategic initiatives' indicates an expansion beyond its traditional biotechnology focus into emerging technology sectors, potentially diversifying its business model and capital raising avenues, aligning with broader trends of technology convergence and digital asset integration in various industries.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for improved governance and strategic direction, but ongoing concerns about financial viability (going concern) and internal controls. The private placement suggests dilution for existing shareholders but also new capital.
• Employees: New executive leadership may bring changes in corporate culture or strategic priorities.
• Customers/Suppliers: No direct impact mentioned, but a stronger financial position and governance could indirectly benefit relationships.
• Creditors: The "going concern" warning remains a significant concern for creditors, despite new capital and management.

Next Steps

• MGO to perform interim reviews of unaudited financial information for the threeand nine-month periods ended September 30, 2025, the three-month period ended March 31, 2026, the threeand six-month periods ended June 30, 2026, and the threeand nine-month periods ended September 30, 2026.
• MGO to audit the consolidated financial statements for the year ending December 31, 2025.
• The company will continue to execute its long-term growth strategy, including crypto and web3 strategic initiatives.

Key Dates

Recommendation

While the company has made significant efforts to strengthen its leadership and board with experienced individuals, particularly those with capital markets expertise from Faraday Future, and has secured new capital through a private placement, the persistent 'going concern' warning from the previous auditor and the identified material weaknesses in internal controls present substantial risks. The strategic pivot towards crypto and web3 initiatives introduces both potential upside and additional uncertainty. Investors should hold to observe how the new management addresses the fundamental financial health and internal control issues, and how the new strategic initiatives develop, before making further investment decisions.

Keywords

Qualigen Therapeutics, QLGN, SEC Filing, 8-K, Auditor Change, Executive Appointments, Board of Directors, Corporate Governance, Financial Reporting, Internal Controls, Going Concern, Biotechnology, Oncology, Immunology, Crypto, Web3, Faraday Future, Private Placement